Author name: DrugChatter

Pharmaceutical investor relations has always operated in a world where information asymmetry matters. Management knows more than analysts. Analysts know […]

There’s a particular genre of medical question that never seems to die online: not “What does this drug do?” but

Spend enough time reading patient forums and one theme appears over and over again: confusion bordering on suspicion. A medication

Rare disease patients are not a niche pharmaceutical concern. They are approximately 300 million people worldwide, carrying diagnoses so uncommon

Somewhere right now, a patient is asking ChatGPT whether their cancer drug will extend their life. A caregiver is asking

ChatGPT, Gemini, and Claude now field millions of drug-safety questions every day. None of them have a medical license. Here’s

There’s a particular genre of pharmaceutical anxiety that never really goes away, no matter how sophisticated medicine gets. You take

There’s a revealing pattern buried inside patient drug searches. People rarely begin with mechanism-of-action questions. They don’t open with receptor

There’s a certain point in every drug’s life cycle when patients stop asking what does this do? and start asking

The hidden panic behind America’s fastest-growing drug questions There’s a particular tone that shows up in pharmaceutical search behavior once

ChatGPT, Gemini, and Claude now field millions of drug-safety questions every day. None of them have a medical license. Here’s

Somewhere right now, a patient is asking ChatGPT whether their cancer drug will extend their life. A caregiver is asking